ALEXANDRIA, Va. – CancerLinQ LLC announced today that it has completed agreements with 36 oncology practices from around the country to begin implementing CancerLinQ™, the groundbreaking health information technology (HIT) platform that will harness big data analytics to help oncologists rapidly improve high-quality care to patients with cancer. CancerLinQ LLC is a wholly-owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO).
“By participating in CancerLinQ, these practices have the opportunity to improve the care of patients but also contribute to a bigger transformation in cancer care,” said ASCO CEO and CancerLinQ LLC Board of Governors Chair Allen S. Lichter, MD, FASCO. “Together, we will be able to see first-hand how physicians can use CancerLinQ in their day-to-day practice to track the quality of their patients’ care and gain important new insights.”
Currently, CancerLinQ is working with the 36 “vanguard” practices to collect clinical data and refine its quality reporting methodologies. There are several novel features of the CancerLinQ software system, including the real-time monitoring and reporting of clinical quality measures. In addition, CancerLinQ will allow clinicians to make better use of electronic health records (EHR) through the use of advanced data visualization capabilities. Access to CancerLinQ will be a major step towards the goal of making the most current oncologic information fully available.
“We are excited to be involved in this cutting-edge initiative that will allow our practice to improve the quality of care for our patients,” said Keith A. Thompson, MD, partner and medical oncologist at Montgomery Cancer Center, and chair of the CancerLinQ Physician Advisory Committee. “Being an early adopter of CancerLinQ not only gives us the chance to contribute to advancing care, but also the chance to be a pioneer in implementing this technological advancement.”
The oncology practices represent a diverse mixture of providers in locations throughout the United States, and include:
- Alaska Women's Cancer Care – Anchorage, Alaska
- Arkansas Cancer Institute – Pine Bluff, Ark.
- Augusta Oncology Associates – Augusta, Ga.
- Cancer Centers of Southwest Oklahoma – Lawton, Duncan and Altus, Okla.
- Cancer Treatment Centers of America Global, Inc.– Nationwide
- Catholic Health Initiatives – Nationwide
- Charleston Hematology Oncology Associates – Charleston, S.C.
- Columbus Oncology and Hematology Associates, an Ohio Oncology Hematology LLC practice – Columbus, Ohio
- Epic Care - Partners in Cancer Care – Antioch, Calif.
- Essex Oncology of North Jersey – Belleville, N.J.
- Fox Valley Hematology & Oncology – Appleton, Wis.
- Health First Cancer Institute – Brevard County, Florida.
- Hematology Oncology Associates of Brooklyn – Brooklyn, N.Y.
- IHA Hematology Oncology Consultants – Ann Arbor, Mich.
- Inova Schar Cancer Institute – Falls Church, Va.
- Katmai Oncology Group – Anchorage, Alaska
- The Longstreet Clinic, P.C. – Gainesville, Ga.
- Lynchburg Hematology Oncology – Lynchburg, Va.
- Marin Cancer Care – Greenbrae, Calif.
- Medical Oncology & Hematology Associates/Cancer Center of Iowa – Des Moines, Iowa
- Medical Oncology Hematology Consultants, PA – Newark, Del.
- Memorial Healthcare System, Memorial Cancer Institute – Hollywood, Pembroke Pines and Aventura, Fla.
- Michiana Hematology-Oncology – Mishawaka, Ind.
- Montgomery Cancer Center – Montgomery, Ala.
- New England Cancer Specialists – Scarborough, Maine
- New Hampshire Oncology-Hematology, P.A. – Hooksett, N.H.
- New Mexico Oncology Hematology Consultants, Ltd. – Albuquerque, N.M.
- Pontchartrain Cancer Center – Covington, La.
- Southcoast Centers for Cancer Care – New Bedford, Mass.
- The Zangmeister Cancer Center, a division of Ohio Oncology Hematology, LLC – Columbus, Ohio
- University Hospitals Seidman Cancer Center – Cleveland, Ohio
- Utah Cancer Specialists – Provo, American Fork, West Jordan, Murray, Salt Lake City, Tooele, Bountiful and Layton, Utah
- Ventura County Hematology Oncology Specialists – Ventura, Oxnard and Camarillo, Calif.
- Virginia Cancer Institute – Richmond, Va.
- Washington Cancer Institute at MedStar Washington Hospital Center –District of Columbia
- West Michigan Cancer Center & Institute for Blood Disorders – Kalamazoo, Mich.
A major announcement on CancerLinQ’s progress is expected later this year at ASCO’s Annual Meeting in Chicago, June 3-7, 2016.
CancerLinQ is being developed using the SAP® Foundation for Health built on the SAP HANA platform, the first of its kind in-memory platform created by SAP that facilitates data integration and provides real-time analysis and reporting capabilities.
CancerLinQ™ is supported in part through the Conquer Cancer Foundation of the American Society of Clinical Oncology, whose generous donors have helped make CancerLinQ possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America®; Chan Soon-Shiong Family Foundation; Genentech BioOncology™; HELSINN; Janssen Oncology; Lilly; Raj Mantena, RPh; Novartis Oncology; Pfizer Oncology; Thomas G. Roberts, Jr., MD and Susan M. DaSilva; and Susan G. Komen®.
CancerLinQ is a project of CancerLinQ LLC. For more information, please visit www.CancerlinQ.org.
Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world’s leading professional organization representing physicians who care for people with cancer. With nearly 40,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit www.asco.org. Patient-oriented cancer information is available at www.cancer.net.
About CancerLinQ LLC
CancerLinQ LLC is a subsidiary of the American Society of Clinical Oncology (ASCO) established for the development and operation of the CancerLinQ™ initiative. CancerLinQ™ is a health information technology (HIT) platform aimed at enhancing and improving the understanding and treatment of cancer. To learn more, visit www.CancerLinQ.org.